Evaxion Unveils Promising Data for AML Vaccine at ASH Meeting

Evaxion Biotech ( (EVAX) ) has issued an announcement.

On December 6, 2025, Evaxion A/S presented new data at the ASH Annual Meeting demonstrating the efficacy of their cancer vaccine candidate, EVX-04, for acute myeloid leukemia (AML). The vaccine, developed using Evaxion’s AI-Immunology™ platform, targets non-conventional ERV tumor antigens and has shown promising results in preclinical models by inducing targeted immune responses and preventing tumor growth. This development could significantly improve treatment options for AML, a disease with high mortality rates and limited current therapies, and highlights the potential of AI-Immunology™ in creating transformative cancer treatments.

The most recent analyst rating on (EVAX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall score is driven by its strong earnings call performance, highlighting strategic achievements and financial stability. However, significant financial challenges and a negative valuation score weigh heavily on the overall assessment. Technical analysis indicates a bearish trend, further impacting the score.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion is a pioneering TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. Their proprietary AI platform is used to create novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion’s pipeline includes clinical-stage oncology vaccines and preclinical treatments for infectious diseases, focusing on high unmet medical needs.

Average Trading Volume: 1,621,501

Technical Sentiment Signal: Sell

Current Market Cap: $33.16M

For an in-depth examination of EVAX stock, go to TipRanks’ Overview page.